NAD+ injections: what they are and what the evidence says

Updated November 3, 2026. For information only, not medical advice. This guide has no affiliate links, and we do not recommend, endorse, rank or price any clinic or product.

In a nutshell

• NAD+ injections and IV drips give NAD+ itself, bypassing the stomach, unlike NMN or NR supplements that you swallow.
• A 2026 systematic review found no eligible outcome trials of IV or intramuscular NAD+ for anti-aging or wellness. The human data we found are small, short, mostly uncontrolled studies.
• Reported side effects in those studies include nausea, cramping, flushing, chest discomfort and, in one clinic-based review, increased heart rate and chest pressure during infusions.
• Evidence rating for “NAD+ injections improve how people function”: Early (small, short, mostly uncontrolled human studies only; we found no controlled outcome trial).

What are NAD+ injections and IV drips?

Basis: Google autocomplete (Nov 1, 2026); PMIDs 41655607, 42787547, 41704678, 31572171; PubMed searches run November 3, 2026.

NAD+ is a molecule every cell uses. “NAD+ injections” and “NAD+ IV therapy” mean giving NAD+ itself by a needle, either as an intravenous (IV) infusion into a vein or as an injection (for example into a muscle). A 2026 narrative review says commercial use of IV NAD+ in wellness settings is increasing, while the evidence for its efficacy and long-term safety remains limited.

In the human studies we found, the NAD+ was given by IV: one pilot study used a 6-hour infusion, and one retrospective clinic review looked at 500 mg infusions on four consecutive days. In PubMed searches on November 3, 2026, we found no human trial of subcutaneous or intramuscular NAD+. A missing result in our search is not proof that none exists, so we cannot say what the evidence is for those routes.

How are they different from NMN and NR?

Basis: PMIDs 41655607, 31572171, 41540253.

NMN and NR are “precursors” you swallow, which the body can turn into NAD+. See NMN vs NR, the NMN guide and the NR guide. A 2026 systematic review found that in humans oral NR and NMN consistently raised blood NAD-related markers and were generally well tolerated over weeks to months, while effects on functional and other health outcomes were heterogeneous and often null.

Injections skip the stomach, but that does not make them better. In the 6-hour infusion pilot, plasma NAD+ and its metabolites did not change until after 2 hours, and the authors described the infused NAD+ as rapidly and completely removed from plasma for at least the first 2 hours. That was a small, uncontrolled study of how the body handles the infusion, not of whether it helps anyone.

What does the research show?

Basis: PMIDs 41655607, 42787547, 41704678, 31572171, 41083806, 40275690.

• Systematic review (2026, Ageing Research Reviews). Gallagher and Emmanuel included 113 studies (33 in humans). They found no eligible outcome trials of IV or intramuscular NAD+ itself for anti-aging or wellness. One nonrandomized IV NMN study met their criteria and mainly gave short-term safety and biomarker information. An IV NAD+ pharmacokinetic pilot was treated as context only. They concluded clinical effectiveness for anti-aging or wellness is inconclusive and that larger randomized trials are needed, particularly for injected or infused approaches. One author discloses owning an organization that provides administrative services to an aesthetics clinic that does not offer NAD+ infusions or supplements.
• Narrative review (2026, Frontiers in Aging). Alangari and colleagues describe the human evidence on IV NAD+ as sparse: small uncontrolled studies, observational work and case reports. Short-term IV NAD+ or NMN was linked to temporary rises in circulating NAD+ and changes in some biomarkers, and some exploratory reports described self-reported improvements in sleep-related outcomes and neurologic symptoms. The authors say the clinical significance is uncertain and that the evidence is insufficient to support routine clinical or wellness use. One of the four authors discloses being employed by a healthcare company.
• Clinic-based review (2026, Frontiers in Aging). Reyna and colleagues reviewed records from a commercial setting, comparing four days of 500 mg IV NAD+ with 500 mg IV NR. It was retrospective and covered 30 days of follow-up. The authors say it provides preliminary real-world evidence of tolerability and short-term safety, and that exploratory metabolic outcomes were variable. All seven authors disclose being employed by a company that operates in that commercial wellness setting, so the work is not independent of it.
• Infusion pilot (2019, Frontiers in Aging Neuroscience). Grant and colleagues tracked plasma and urine NAD+ metabolites during a 6-hour infusion, as above. It measured chemistry, not health outcomes. No competing interests are listed in its PubMed record.

For contrast, oral precursors have far more human trials, and even those have not shown clear gains in function: a 2025 review said human trials of NAD+ precursors have shown limited efficacy, and a 2025 meta-analysis found the evidence does not support NMN or NR for preserving muscle in adults over 60.

Reported side effects and safety questions

Basis: PMIDs 42787547 and 41704678; FDA “FDA reminds compounders to use ingredients suitable for sterile compounding” (opened November 3, 2026).

• From the research. The narrative review reports nausea, cramping, flushing and chest discomfort, and says long-term safety data are lacking. In the clinic-based review, people given IV NAD+ reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions, while those given IV NR had minor tingling in the tongue, jaw and arm and mild cramping. All symptoms resolved when the infusion ended. The NAD+ infusions took longer (97 minutes on average versus 37 for NR) because of those symptoms.
• From the US FDA. FDA has warned that food-grade NAD+ is not suitable for making sterile injectable drugs, because of contamination and endotoxin risk. It says it has received adverse event reports after NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue.

These are reports and a warning, not a measure of how common problems are. We found no long-term safety data.

Questions to ask a clinician

Talk to a clinician first if you are pregnant or breastfeeding, have a history of cancer, take any medicines, or have heart symptoms. We found no safety data for these groups in our sources. This is general information, not personal advice.

Basis: our sources above; the NIH Office of Dietary Supplements says to tell your health care providers about supplements you take and to be cautious with supplements in pregnancy or when nursing.

If you are considering NAD+ injections or an IV drip, questions worth asking include:

• What exactly is in the product, who made it, and is it a prescription product from a licensed pharmacy?
• What evidence supports it for my goal? (The research above found no outcome trials.)
• What side effects have patients reported, and how is the infusion rate set and monitored?
• What happens if I have chest pressure, a fast heart rate or severe chills?
• Who do I report a bad reaction to?
• Are there other steps for my goal, such as the basics in longevity supplements for beginners?

FAQ

Are NAD+ injections safe?

We cannot say they are. The human data are small and mostly uncontrolled, long-term safety data are lacking. A clinic-based review reported chest pressure and increased heart rate during IV NAD+ infusions. Talk to a clinician first.

Basis: Google autocomplete (Nov 1, 2026); PMIDs 42787547, 41704678.

What are the side effects of NAD+ injections?

Reported effects include nausea, cramping, flushing and chest discomfort, and in one clinic-based review moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions, which resolved when the infusion ended. Long-term effects are not known.

Basis: Google autocomplete (Nov 1, 2026); PMIDs 42787547, 41704678.

What are the benefits of NAD+ injections?

We found no controlled human outcome trial showing a benefit. A 2026 systematic review found no eligible outcome trials of IV or intramuscular NAD+ for anti-aging or wellness. A narrative review mentions exploratory self-reported changes in sleep and neurologic symptoms, but calls their significance uncertain.

Basis: Google autocomplete (Nov 1, 2026); PMIDs 41655607, 42787547.

Are NAD+ injections safe during pregnancy or breastfeeding?

We found no safety data for pregnancy or breastfeeding in our sources, so we cannot say. If you are pregnant or breastfeeding, ask a clinician before considering any injection or infusion. The NIH Office of Dietary Supplements also urges caution with supplements in pregnancy or when nursing.

Basis: Google autocomplete (Nov 1, 2026); NIH ODS “Dietary Supplements: What You Need to Know”; no pregnancy data found in PMIDs 41655607, 42787547, 41704678.

How much do NAD+ injections cost?

We do not list prices or clinics, and the research we cite does not report prices. If you are weighing cost, ask any provider for a written breakdown of what is included, and and compare that cost with the evidence above, which found no outcome trials.

Basis: Google autocomplete (Nov 1, 2026); policy of this site (no prices, clinics or recommendations).

What this means for you

What this means for you

• What they are: NAD+ given by IV drip or injection, which is different from swallowing NMN or NR.
• Evidence: we found no controlled human outcome trial. A 2026 systematic review found none for IV or intramuscular NAD+ (Early at best: small, short, mostly uncontrolled studies).
• Safety: reported effects include nausea, cramping, flushing, chest discomfort, and raised heart rate and chest pressure during infusions. The safety section above also covers a warning about ingredient quality.
• Independence: the clinic-based study’s authors all disclose being employed by a company in that commercial setting.
• Before you decide: talk to a clinician and ask the questions above. We do not recommend or endorse injections, clinics or brands.
• Doses mentioned (500 mg a day for four days; 3 µmol per minute for 6 hours) describe the studies, not advice.

Sources

Pages were opened on November 3, 2026.

1. Gallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev, April 2026. PubMed
2. Alangari A et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging 2026. PubMed
3. Reyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging 2026. PubMed
4. Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Front Aging Neurosci 2019. PubMed
5. Vinten KT et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab 2025. PubMed
6. Prokopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025. PubMed
7. Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab 2026. PubMed (opened November 1, 2026)
8. US Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding (the page text we read shows no date).
9. NIH Office of Dietary Supplements (US). Dietary Supplements: What You Need to Know, fact sheet for consumers (updated January 4, 2023).

This article is for information only and is not medical advice. Speak to a healthcare professional before changing medication or supplements.